Nike’s Importation Fine Serves As A Lesson For Drug Firms In China
This article was originally published in PharmAsia News
Beijing issued Nike a RMB 4.87 million fine for using double standards for an imported product in China, prompting legal and industry watchers to warn multinational companies to keep prices competitive or they could find themselves under tighter scrutiny.
You may also be interested in...
A new dual receipting system, a potential registry for sales reps, and rules over false advertisements and promotion are just some of the many and growing challenges pressuring pharna corporate compliance officers in China, experts attending a recent conference said.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.